Compare AstraZeneca plc (AZN) vs KraneShares Hang Seng TECH Index ETF (KTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs KraneShares Hang Seng TECH Index ETF — how do they compare? AstraZeneca plc trades at $168.85 (market cap $253.13B), while KraneShares Hang Seng TECH Index ETF trades at $13.35. The key difference: AstraZeneca plc pays a 1.92% dividend while KraneShares Hang Seng TECH Index ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, KraneShares Hang Seng TECH Index ETF nearer its low. Which is the better fit depends on your goals.
| AZN | KTEC | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $209.48 | $19.51 |
52-Week Low | $137.44 | $12.00 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
KTEC trades at $12.90, down 1.07% with mixed technical signals showing bullish moving averages but overbought RSI conditions. The stock faces consolidation near key support/resistance at $13. Fundamental data remains limited pending updated financial disclosures from recent SEC filings.
The technical setup suggests near-term consolidation while awaiting fundamental catalysts. Investment opportunity depends on upcoming earnings validation, though limited institutional coverage and thin financial data increase reliance on technical momentum for directional bias.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About KraneShares Hang Seng TECH Index ETF
KTEC tracks the Hang Seng TECH Index, providing targeted exposure to the 30 largest technology companies listed on the Hong Kong Stock Exchange. It focuses on innovative, internet-based businesses across sectors like e-commerce, fintech, cloud computing, and digital technology.
Read more on KTEC →
